13 October 2022 | News
Strengthens commitment to India with further expansion
AstraZeneca India, the global capability centre of leading science-led biopharmaceutical company AstraZeneca, plans to further expand its Clinical Data and Insights (CDI) division, after the new unit tripled its headcount within its first year of launch in Bengaluru. To accommodate this expansion, the Bengaluru centre recently leased additional space that was inaugurated by key global leaders on 13 October.
The continued investment will include hiring additional data experts, deepening the role that India plays in supporting and driving AstraZeneca’s growing portfolio of new medicines by further strengthening the management of global clinical data. It works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3 with an integrated end-to-end approach for clinical data, analytics, insights and risk management.
The CDI division today has over one hundred employees (Data managers, Programmers, Data Scientists, Data Standards experts), forming part of a global network spread across 6 countries.
Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited (AZIPL) said, “With over 100 employees, the Bengaluru team is strategically supporting the global trials, and will further strengthen its role in supporting AstraZeneca's aspiration to be pioneer in science and transform patient-outcomes.”
The CDI division in Bengaluru is a critical advancement to support a growing global portfolio and build on internal data expertise. In addition to Data Management and Data Standards, functions like Centralized Monitoring, TRISARC (Trials Safety Review Centre) and SASP comprising of safety patient data review experts are also setting up their teams in the Bengaluru centre.